Zentiva spurns Sanofi's buyout offer

Sanofi-Aventis hasn't been so lucky in its bid to buy the Czech generics maker Zentiva. The object of Sanofi's desire rebuffed the $2 billion takeover offer, as its board of directors told shareholders that the price doesn't fairly reflect the company's "underlying value" and "future prospects." Zentiva enumerates its reasoning--arrived at with the help of Merrill Lynch, which it hired to evaluate the offer--in a document available at the link below. Sanofi, as you know, already owns a 24.9 percent interest in the company, which it bought in 2006 for $523.9 million from Warburg Pincus.

You'll recall that last month a Czech financial company, PPF Group, offered 950 koruna per share for Zentiva, and the company promptly announced its contempt for that price. Sanofi then offered 1,050 koruna; we now know what Zentiva management thinks of that. And here's where things get really interesting: Will PPF come back with a higher offer? And if so, will Sanofi counter? Zentiva management seems to think that a bidding war is in order; we'll see whether its suitors do, too.

- read Zentiva's release
- see the story at Trading Markets
- check out the New York Times Deal Blog's take

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.